Pharmather's KETARx approved by FDA

Executive Summary

• The U.S. Food and Drug Administration (FDA) granted approval to Pharmather Holdings Ltd.'s ketamine product, KETARx, on August 8, 2025, for use in surgical pain management.
• This approval positions Pharmather to expand its pipeline into mental health, neurological disorders, and chronic pain management, leveraging the strategic importance of ketamine as an essential medicine.
• The company highlights a significant market opportunity, citing a global ketamine market projected to grow from $750 million to $3.42 billion by 2034, alongside existing demand drivers such as FDA drug shortages and VA coverage for veterans.

Key Details

• Product Name: KETARx (ketamine).
• Regulatory Body: U.S. Food and Drug Administration (FDA).
• Approval Date: August 8, 2025.
• Indication: Surgical pain management.
• Strategic Context: The approval supports Pharmather's goal of becoming a global leader in ketamine-based pharmaceuticals for mental health, neurological, and pain disorders.
• Market Data:
  • Current global ketamine market value: $750 million.
  • Projected market value by 2034: $3.42 billion.
  • Compound Annual Growth Rate (CAGR): 16.4%.
  • Comparison product (Spravato/esketamine) sales run rate: $1.6 billion, with guidance of $3–3.5 billion by 2027–2028.
• Pipeline Expansion Areas:
  • Mental health conditions (e.g., depression).
  • Neurological disorders (e.g., Parkinson’s disease, amyotrophic lateral sclerosis).
  • Rare or chronic pain management (e.g., complex regional pain syndrome).
• Supply Chain Context: Ketamine has been on the FDA drug shortage list since February 2018.
• Regulatory Environment:
  • FDA issued a compounding risk alert on October 10, 2024 (noted as 20234 in text), warning against compounded ketamine for psychiatric disorders.
  • FDA Commissioner Marty Makary established a national priority voucher program to expedite access to safe treatments.
  • Veterans Health Administration currently approves and finances ketamine infusions for veterans with depression, PTSD, and chronic pain.

Notable Quotes

• Fabio Chianelli, Founder, Chairman and CEO: "Today marks a new chapter for Pharmather. With FDA approval for ketamine now in hand, we are closer to realizing our goal of becoming a global leader in ketamine-based pharmaceuticals. This historic FDA approval for Pharmather is a testament to years of dedicated development, signalling a new era of growth. We remain steadfast in our mission to harness the pharmaceutical potential of ketamine for a range of mental health, neurological and pain disorders."